Circulatory and Ventilatory Power: Characterization in Patients with Coronary Artery Disease

Viviane Castello-Simões¹, Vinícius Minatel¹, Marlus Karsten¹,², Rodrigo Polaquini Simões¹, Natália Maria Perseguini¹, Juliana Cristina Milan¹, Ross Arena¹, Laura Maria Tomazi Neves¹, Audrey Borghi-Silva¹, Aparecida Maria Catai⁷

Laboratório de Fisiologia Integrativa, Faculdade de Ciências Aplicadas da Saúde, Universidade de Illinois Chicago¹, Chicago, IL – USA

Abstract

Background: Circulatory power (CP) and ventilatory power (VP) are indices that have been used for the clinical evaluation of patients with heart failure; however, no study has evaluated these indices in patients with coronary artery disease (CAD) without heart failure.

Objective: To characterize both indices in patients with CAD compared with healthy controls.

Methods: Eighty-seven men [CAD group = 42 subjects and healthy control group (CG) = 45 subjects] aged 40–65 years were included. Cardiopulmonary exercise testing was performed on a treadmill and the following parameters were measured: 1) peak oxygen consumption (VO₂), 2) peak heart rate (HR), 3) peak blood pressure (BP), 4) peak rate-pressure product (peak systolic HR x peak BP), 5) peak oxygen pulse (peak VO₂/peak HR), 6) oxygen uptake efficiency (OUES), 7) carbon dioxide production efficiency (minute ventilation/carbon dioxide production slope), 8) CP (peak VO₂ x peak systolic BP) and 9) VP (peak systolic BP/carbon dioxide production efficiency).

Results: The CAD group had significantly lower values for peak VO₂ (p < 0.001), peak HR (p < 0.001), peak systolic BP (p < 0.001), peak rate-pressure product (p < 0.001), peak oxygen pulse (p = 0.008), OUES (p < 0.001), CP (p < 0.001), and VP (p < 0.001) and significantly higher values for peak diastolic BP (p = 0.004) and carbon dioxide production efficiency (p < 0.001) compared with CG. Stepwise regression analysis showed that CP was influenced by group (R² = 0.44, p < 0.001) and VP was influenced by both group and number of vessels with stenosis after treatment (interaction effects: R² = 0.46, p < 0.001).

Conclusion: The indices CP and VP were lower in men with CAD than healthy controls. (Arq Bras Cardiol. 2015; 104(6):476-486)

Keywords: Exercise; Oxygen Uptake; Cardiopulmonary Exercise; Cardiovascular Disease, Adults.

Introduction

Cardiopulmonary exercise testing (CPX) is considered the gold standard for evaluating the response to aerobic exertion in patients with cardiovascular diseases to determine the physiological mechanisms of exercise intolerance¹. Some indices, such as peak oxygen consumption (VO₂), carbon dioxide production efficiency derived from the linear relationship between minute ventilation (VE) and carbon dioxide production (VCO₂) (VE/VCO₂ slope)² and oxygen uptake efficiency (OUES), derived from the linear relationship between VO₂ and VE¹⁴, have been used to assess healthy subjects³⁴, patients with heart failure³⁸ and with other forms of heart disease⁹, such as coronary artery disease (CAD)¹⁰¹¹. Circulatory power (CP) is a less frequently assessed variable obtained from CPX and calculated as the product of peak VO₂ and peak systolic blood pressure (BP). CP has shown some potential for clinical utility¹²¹⁵ and has been proposed as a surrogate for cardiac power. This index has also been shown to be an independent predictor of mortality, with a lower CP portending a worse prognosis¹³¹⁴. More recently, Forman et al. (2012)¹⁶ introduced and evaluated the prognostic use of a novel index, named ventilatory power (VP), which was calculated by dividing peak systolic BP by the VE/VCO₂ slope. According to the authors, better prognosis is reflected by a higher VP value, i.e., greater systolic BP and/or lower VE/VCO₂ slope.

While these variables have been assessed in heart failure cohorts, we are unaware of any previous study that evaluated the CP and VP indices in CAD patients without heart failure who were managed using standard medication, angioplasty or coronary artery bypass graft (CABG) surgery. Thus, the purpose of this study was to test the hypothesis that both CP and VP would be significantly lower in these CAD patients.
compared with healthy controls; therefore, could provide another potentially valuable measure of cardiopulmonary function in these patients.

Methods

This is an observational, cross-sectional, comparative study.

Participants

Men between 40–65 years of age were allocated to two groups: 1) patients with CAD confirmed by cardiac catheterization (CAD-G) and without heart failure and 2) an apparently healthy control group (CG). Subjects in CAD-G were recruited through a local hospital (hemodynamic section) and CG subjects were identified from a registry database in our laboratory and contacted to determine interest. Subjects were invited to participate in this study between June 2008 and April 2013. The inclusion criteria for CAD-G were: 1) CAD patients or without myocardial infarction (1 month to 3 years since the event) optimally managed using current standard pharmacologic regimens and potentially: a) mechanical or chemical reperfusion and/or b) CABG surgery (6 months to 3 years post-surgery) and 2) preserved left ventricular function with an ejection fraction > 50%. Inclusion criteria for CG were: 1) apparently healthy based on clinical examination and 2) no use of prescription medications. The exclusion criteria for both groups were: 1) body mass index (BMI) ≥ 30 kg/m², 2) use of tobacco, 3) habitual drinking or illegal drug use, 4) orthopedic limitations, 5) neurological disease, 6) diabetes, 7) uncontrolled systemic arterial hypertension, 8) functional capacity ≤ 4 metabolic equivalents, 9) lung diseases, 10) inappropriate behavior of BP to exertion, 11) malignant ventricular arrhythmia, 12) atrial fibrillation, 13) complex ectopic ventricular beats, 14) supraventricular or sinus tachycardia, 15) 2º and 3º atrioventricular block, 16) fixed frequency pacemaker, and 17) participation in a regular exercise program in the last 6 months. This study was approved by the local Ethics Committee and conducted in accordance with the Declaration of Helsinki (1975). Written informed consent was obtained from each individual before the initiation of the study.

Clinical examination

Prior to study initiation, all subjects underwent a clinical evaluation to characterize their clinical status. The evaluation comprised: 1) clinical cardiac examination; 2) resting ECG (Ecafix TC 500, São Paulo, São Paulo, Brazil); 3) maximal standard exercise test on a treadmill (DIGISTRESS Vega, Digitronica, Belo Horizonte, Minas Gerais, Brazil); and 4) laboratory measurements: glycemia, hemoglobin, lipid profile, urea, creatinine, and uric acid. Subjects discontinued pharmacological prior to the exercise test, which was conducted by a physician using the Bruce protocol in accordance with the American Thoracic Society recommendations. Symptoms of dyspnea and leg fatigue were assessed using the modified Borg scale and all subjects were asked about the occurrence of angina at each stage of the exercise protocol. After a minimum resting period of 48 h, all eligible subjects performed CPX.

Cardiopulmonary exercise testing (CPX)

On the same day as CPX, the maximal walking velocity on a treadmill (Master ATL, Inbramed, Porto Alegre, Rio Grande do Sul, Brazil) was determined for all subjects. The starting treadmill speed was set at 3.0 km/h without elevation, with subsequent 0.5 km/h increases in speed every 30 s. At this point, the speed was increased or decreased by 0.1 km/h until the subjects reached a maximal comfortable walking cadence without running. After determining the maximal walking velocity, symptom-limited CPX was performed using a calibrated ventilatory expired gas unit (CPX-D, Medical Graphics, Saint Paul, Minnesota, United States) according to a ramping protocol: 1) 1 min at rest; 2) an incremental phase, beginning at an initial speed of 0.8 km/h until maximal walking velocity was reached; 3) 0.5% increase in incline grade every 15 s; 4) 1 min of active recovery at 3.0 km/h; and 5) 5 min of passive recovery. Ventilatory expired gases were collected breath-by-breath and calculated as moving means after every eight respiratory cycles (Breeze Suite 6.4.1, Medical Graphics, Saint Paul, Minnesota, United States). The criteria for test termination were based on current exercise guidelines.

Throughout CPX, ECG (12 simultaneous leads) and heart rate (HR) were monitored and registered (WinCardio, Micromed, Brasilia, Distrito Federal, Brazil). Delta of HR was expressed as peak HR minus HR at rest and the predicted maximum HR was calculated as 220 minus age in years. The BP was measured at rest, every 2 min during the test and throughout recovery (BD, São Paulo, São Paulo, Brazil). Perceived exertion (symptoms of dyspnea and leg fatigue) was assessed using the modified Borg scale and all subjects were asked about the occurrence of angina and symptoms at each stage of the exercise protocol, according to current exercise guidelines.

Peak VO₂ and peak respiratory exchange ratio (RER) (defined as the ratio between VCO₂ and VO₂) were expressed as the highest averaged values observed during the last 30 s of exercise. The VE/VCO₂ slope and the OUES were calculated from the initiation of exercise to peak. The VE/VCO₂ slope was obtained by analyzing the linear relationship between VE and VCO₂ with VE on the y-axis and VCO₂ on the x-axis. The OUES was obtained by analyzing the linear relationship between VO₂ and VE, with VO₂ on the y-axis and the log-transformation of VE on the x-axis.

Other variables were calculated: 1) peak rate-pressure product (RPP) = product of peak systolic BP and peak HR; 2) peak oxygen pulse = peak VO₂ divided by the peak HR; 3) CP = product of peak VO₂ and peak systolic BP; and 4) VP = peak systolic BP divided by the VE/VCO₂ slope.

Statistical analysis

Based on a pilot study using VP and CP as endpoints (CAD-G = 5 individuals; CG = 5 individuals), a sample size for the current study that would provide sufficient statistical power (β = 0.8) to detect an important difference (α = 0.05) was estimated to be 12 and 21 subjects (VP and CP, respectively) in each group (GPower software package, version 3.1.6, Kiel, Schleswig–Holstein, Germany). The Kolmogorov–Smirnov test was used to investigate the data distribution. Continuous
quantitative variables were expressed as mean ± standard deviation (SD) and categorical variables as absolute values and percentages. Subjective data (dyspnea and leg fatigue) were expressed as median [minimum − maximum]. The unpaired Student’s t-test was used to compare the continuous quantitative variables between CAD-G and CG. Fisher’s exact test was used to compare the categorical variables between groups and the situations after versus before treatment. Stepwise regression analysis was performed to determine the possible influence of group, medications, risk factors (hypertension and dyslipidemia) and number of vessels with stenosis after treatment on the main studied variables (HR, BP, VO2, V/E/CO2, slope, CP and VP). One-way ANOVA (followed by Tukey’s post-hoc test) was performed after subdividing CAD-G according to the type of event and treatment to assess possible differences between subgroups. Pearson correlation analysis was applied to determine the relationships between CP or VP and peak VO2, OUES, RPP and oxygen pulse. The probability of type 1 error occurrence was established at 5% for all tests (p < 0.05). SPSS (version 17.0, SPSS Inc., Chicago, Illinois, United States) was used to perform the statistical analysis.

Results

Of a total of 97 apparently healthy subjects, we excluded 52 subjects aged < 40 or > 65 years. Forty-five subjects were contacted and recruited for CG. In relation to CAD-G, 54 subjects were recruited; however, 12 were excluded after clinical examination because of BMI ≥ 30 kg/m2 (n = 2), use of tobacco (n = 2), chronic obstructive pulmonary disease (n = 2), presence of cardiac arrhythmias (n = 2), uncontrolled systemic arterial hypertension (n = 1), restenosis after mechanical reperfusion (n = 2), and inability to perform the maximal standard exercise test (n = 1). Thus, our sample consisted of 87 men (45 in CG and 42 in CAD-G). It is important to emphasize that a preliminary analysis (one-way ANOVA) was performed by dividing CAD-G into subgroups according to the type event and treatment. There were no significant differences between subgroups pertinent to any of the studied variables: thus, we pooled the data of all patients in CAD-G.

The characteristics of CAD-G and CG are presented in Table 1. No significant difference was found between groups with regard to age (p = 0.087), height (p = 0.318), weight (p = 0.165), and BMI (p = 0.222). In relation to the clinical data of CAD-G before treatment, most patients had two vessels with stenosis (33%), and considering only the 41 subjects with stenosis, the vessel most affected was the anterior descending artery (78%). After treatment, most patients had one-vessel stenosis (48%), and considering only the 29 subjects with stenosis, the vessel most affected was the left circumflex artery (45%). Most subjects in CAD-G (76%) previously suffered a myocardial infarction and had been managed in the following ways: 1) only with standard medication (2%), 2) angioplasty (60%), and 3) CABG (14%). The remaining subjects in the experimental group had CAD with no previous myocardial infarction (24%) and had been managed with: 1) medication only (5%), 2) angioplasty (7%), and 3) CABG (12%) (Table 1). Of the 42 subjects in CAD-G, 15 had a past smoking history and none was diabetic; furthermore, 38 subjects were diagnosed with systemic arterial hypertension and 39 with dyslipidemia; both risk factors were managed pharmacologically. Of the 45 subjects in CG, three had a past smoking history and none had a diagnosis of diabetes, systemic arterial hypertension or dyslipidemia. None of the CG subjects used any prescribed medication (Table 1).

Table 2 shows the comparison between groups in relation to peak variables obtained during the maximal standard exercise test that preceded CPX. CAD-G had significantly lower values for HR (p < 0.001) and systolic BP (p = 0.012) compared with CG. In addition, CAD-G had significantly higher values for diastolic BP (p = 0.016) and symptoms of dyspnea and leg fatigue (p < 0.001 and p = 0.008, respectively) compared with CG. Furthermore, the occurrence of angina (reported by the patients) was present in only 5% of CAD-G (n = 2), whereas it was not present in any subjects in CG. ECG recordings revealed that 7% of CAD-G (n = 3) presented ST segment depression < 2 mm and 5% (n = 2) presented ST segment depression ≥ 2 mm; there was no abnormality in ECG in CG (Table 2).

During CPX, the maximum walking velocity obtained was significantly lower in CAD-G (6.2 ± 0.4 km/h, range: 5.7–7 km/h) than CG (7.1 ± 0.7 km/h, range: 6.8–8 km/h in CG) (p < 0.001); however, there were no significant differences with respect to maximum grade obtained between groups: 12.8 ± 4.9 % (range: 3.5–22 %) in CAD-G and 11.6 ± 5.6% (range: 1.5–21 %) in CG (p = 0.311). Key CPX variables and aerobic functional classification according to American Heart Association (AHA) guidelines44 for CAD-G and CG are presented in Table 3. There were no significant differences in HR and BP between groups during rest. During peak effort, CAD-G had significantly lower values for VO2 (p < 0.001), HR (p < 0.001), % of predicted maximum HR (p < 0.001), delta of HR (p < 0.001), systolic BP (p < 0.001), RPP (p < 0.001), oxygen pulse (p = 0.008), OUES (p < 0.001), CP (p < 0.001), and VP (p < 0.001) compared with CG. In addition, during peak effort, CAD-G had significantly higher values for diastolic BP (p < 0.001), the V/E/CO2 slope (p = 0.004), symptoms of dyspnea and leg fatigue (p = 0.008 and p < 0.001, respectively) compared with CG. Furthermore, angina (reported by the patients) occurred only in 2% of CAD-G (n = 1) and was not present in any subjects in CG. There were no ECG abnormalities in either group (CAD-G and CG) during CPX (Table 3). With regard to the aerobic functional classification according to AHA guidelines23, Table 3 shows that the majority of patients of CAD-G had a weak aerobic classification (53%), while in CG slightly more than half of subjects had a regular level of aerobic classification (53%).

Stepwise regression analysis was performed to determine the possible influence of group, medications, risk factors (hypertension and dyslipidemia), and number of vessels with stenosis after treatment on CPX variables of interest. We found that none of the variables were affected by risk factors. However, the following influences were determined: 1) peak VO2 was influenced by group and medications (interaction effects: R2 = 0.46, β of group = 0.95 and β of medications = −0.35, p < 0.001); 2) peak systolic BP was influenced only by medications (R2 = 0.11, β = 0.34, p < 0.001);
| Table 1 – Characteristics of CAD-G and CG | CAD-G (n = 42) | CG (n = 45) | p value |
|----------------------------------------|----------------|-------------|---------|
| Age, years                             | 54.3 ± 6.6     | 53.9 ± 6.4  | 0.087   |
| Anthropometry                          |                |             |         |
| Height, m                              | 1.70 ± 0.07    | 1.73 ± 0.13 | 0.318   |
| Weight, kg                             | 79.0 ± 12.3    | 76.9 ± 9.9  | 0.165   |
| Body mass index, kg/m²                 | 27 ± 3.9       | 26 ± 5.9    | 0.222   |
| Cardiac function                       |                |             |         |
| LVEF, %                                | 63.9 ± 7.1     | -           | -       |
| Vessels with stenosis, n (%)           |                |             |         |
| Without stenosis                       | 1 (2)          | 13 (31)     | < 0.001 |
| One diseased vessel                    | 10 (24)        | 20 (48)     | 0.039   |
| Two diseased vessels                   | 14 (33)        | 6 (14)      | 0.071   |
| Three diseased vessels                 | 8 (19)         | 3 (7)       | 0.194   |
| Multivessel (> 3 diseased vessels)    | 9 (22)         | 0           | 0.002   |
| Location of stenosis (> 50%), n (%)   |                |             |         |
| Anterior descending artery             | 32 (78)        | 8 (28)      | < 0.001 |
| Left circumflex artery                 | 26 (63)        | 13 (45)     | 0.147   |
| Right coronary artery                  | 24 (58)        | 10 (34)     | 0.056   |
| Diagonal arteries                      | 8 (19)         | 6 (21)      | 1.000   |
| Marginal arteries                      | 4 (10)         | 1 (3)       | 0.394   |
| CAD characteristics, n (%)            |                |             |         |
| With myocardial infarction             |                |             |         |
| Treated only with medication           | 1 (2)          | -           | -       |
| Treated with angioplasty               | 25 (60)        | -           | -       |
| Treated with CABG                      | 6 (14)         | -           | -       |
| Without myocardial infarction          |                |             |         |
| Treated only with medication           | 2 (5)          | -           | -       |
| Treated with angioplasty               | 3 (7)          | -           | -       |
| Treated with CABG                      | 5 (12)         | -           | -       |
| Risk factors, n (%)                    |                |             |         |
| History of smoking                     | 15 (36)        | 3 (7)       | < 0.001 |
| Diabetes                               | 0              | 0           | -       |
| Arterial hypertension                  | 38 (90)        | 0           | < 0.001 |
| Dyslipidemia                           | 39 (93)        | 0           | < 0.001 |
| Medications, n (%)                     |                |             |         |
| Beta-blocker                           | 37 (88)        | -           | -       |
| ACE inhibitor                          | 24 (57)        | -           | -       |
| Diuretic                               | 12 (29)        | -           | -       |
| Lipid-lowering                         | 39 (93)        | -           | -       |
| Antiplatelet/ anticoagulant            | 42 (100)       | -           | -       |

Data are presented as mean ± SD or absolute values (%). CAD-G: coronary arterial disease group; CG: control group; n: number of individuals; LVEF: left ventricular ejection fraction; CABG: coronary artery bypass grafting; (-): not applicable; ACE: angiotensin converting enzyme. Unpaired Student’s t-test and Fisher’s exact test.
VE/VCO₂ slope was influenced only by group (R² = 0.08, β = 0.36, p < 0.001); 4) CP was influenced only by group (R² = 0.44, β = 0.67, p < 0.001); and 5) VP was influenced by group and number of vessels with stenosis after treatment (interaction effects: R² = 0.46, β of group = 0.62 and β of number of vessels with stenosis after treatment = −0.30, p < 0.001).

Figure 1 illustrates a significant correlation between both CP and VP and peak VO₂, considering the subjects by aerobic functional classification according to AHA guidelines. For better visualization of Figure 1, only those with a weak (n = 22) and regular level of classification (n = 14) in CAD-G and only those with regular (n = 24) and good level of classification (n = 15) in CG were included in the statistical analysis and presented in this figure. With respect to CP, there was a strong positive correlation with peak VO₂ (Figure 1A, r = 0.91, p < 0.001), while VP showed a moderate positive correlation with peak VO₂ (Figure 1B, r = 0.43, p < 0.001). Figure 2 illustrates the significant correlations between CP and VP and other CPX indices (OUES, RPP and oxygen pulse), considering the entire study cohort. CP exhibited a strong positive correlation with OUES (Figure 2A, r = 0.75, p < 0.001) and peak RPP (Figure 2C, r = 0.74, p < 0.001) and moderate positive correlation with peak oxygen pulse (Figure 2E, r = 0.59, p < 0.001); with regard to VP there was a moderate positive correlation with OUES (Figure 2B, r = 0.55, p < 0.001), peak RPP (Figure 2D, r = 0.58, p < 0.001) and peak oxygen pulse (Figure 2F, r = 0.55, p < 0.001).

### Discussion

The main findings from this study were: 1) CAD patients without heart failure under current standard pharmacologic regimens, angioplasty, or surgical management had lower CP and VP values compared with CG; 2) the indices CP and VP correlated positively with VO₂ according to aerobic functional classification as per AHA guidelines; and 3) the response of CPX and the metabolic, ventilator, and cardiovascular variables demonstrated lower functional capacity and poorer exercise response in subjects with CAD.

To the best of our knowledge, this is the first study to introduce CP and VP indices in the functional evaluation of subjects with CAD without heart failure compared with apparently healthy controls. Thus, our findings have a potential clinical relevance given that these indices may be used to assess the functional significance of the disease process. The potential advantage of CP and VP indices is that both are simple and noninvasive and synergistically combine singular indices related to cardiopulmonary integrity and health.

### Sample characteristics

As listed in Table 1, the groups did not differ in terms of age; this is an important consideration as it is known that aging affects peak VO₂. In addition, we did not include obese individuals because they present with abnormal exercise responses unique to body habitus, which could have confounded our results. We included patients with controlled systemic arterial hypertension and controlled dyslipidemia in CAD-G; however, we observed (using stepwise regression analysis) that these factors did not influence the CPX response.

### Cardiopulmonary exercise testing (CPX)

CP and VP were lower in CAD-G than in CG; the same observation was applicable to the following peak variables obtained during CPX: VO₂, HR, % of predicted maximum HR, delta of HR, systolic BP, RPP, oxygen pulse, and OUES. Moreover, higher values of peak diastolic BP and the VE/VCO₂ slope were found in CAD-G. Pharmacologic management, such as angiotensin-converting enzyme inhibitors, diuretics, and particularly beta-blockers, may contribute to the exercise response because CAD-G presented with lower values of peak systolic BP, peak HR, and peak VO₂ in relation to CG during CPX. In addition, during the maximal standard exercise test performed with suspended pharmacological therapy, CAD-G presented with a higher peak HR (approximately 7%) than CPX, in which the subjects were undergoing pharmacological therapy. Although these medications may have influenced our results, they are considered standard of care therapy for these patients, and beta-blocker withdrawal can increase the risk of heart events. Because VO₂ is present in the formula of CP and BP is present in the formula of CP and VP, it is important to consider that medications...

### Table 2 – Peak variables obtained during maximal standard exercise testing for clinical evaluation in CAD-G and CG

|                         | CAD-G (n = 42) | CG (n = 45) | p value |
|-------------------------|---------------|-------------|---------|
| HR, bpm                 | 144.9 ± 20.0  | 169.9 ± 19.1| < 0.001 |
| Systolic BP, mmHg       | 175.7 ± 26.5  | 189.5 ± 22.3| 0.012   |
| Diastolic BP, mmHg      | 91.3 ± 11.8   | 85.0 ± 11.2 | 0.016   |
| Symptoms of dyspnea (0–10) | 7.0 [2 - 10] | 4.0 [2 - 6] | < 0.001 |
| Leg fatigue (0–10)      | 6.0 [0 - 10]  | 4.5 [2 - 5] | 0.008   |
| Angina, n (%)           | 2 (5)         | 0           | 0.230   |
| ST segment depression < 2 mm, n (%) | 3 (7) | 0 | 0.108   |
| ST segment depression ≥ 2 mm, n (%) | 2 (5) | 0 | 0.230   |

Data are presented as mean ± SD, median [minimum - maximum] or absolute values (%). CAD-G: coronary artery disease group; CG: control group; n: number of subjects; HR: heart rate; BP: blood pressure. Unpaired Student’s t-test and Fisher’s exact test.
Table 3 – Variables obtained during cardiopulmonary exercise testing and aerobic functional classification according to AHA guidelines in CAD-G and CG

| Variable                                      | CAD-G (n = 42) | CG (n = 45) | p value |
|-----------------------------------------------|----------------|-------------|---------|
| **Rest**                                      |                |             |         |
| HR, bpm                                       | 65.9 ± 11      | 69.7 ± 11   | 0.110   |
| Systolic BP, mmHg                             | 120.7 ± 10.7   | 117.4 ± 18.7| 0.298   |
| Diastolic BP, mmHg                            | 82.6 ± 7.6     | 79.7 ± 9.6  | 0.103   |
| **Peak**                                      |                |             |         |
| VO$_2$, ml.kg$^{-1}$min$^{-1}$                | 22.9 ± 4.8     | 32.7 ± 6.6  | < 0.001 |
| RER                                           | 1.11 ± 0.07    | 1.12 ± 0.08 | 0.738   |
| HR, bpm                                       | 135.4 ± 22.2   | 165.0 ± 18.7| < 0.001 |
| % of predicted maximum HR                     | 81.8 ± 13.4    | 97.7 ± 9.9  | < 0.001 |
| Delta of HR, bpm                              | 52.7 ± 23.1    | 85.2 ± 20.7 | < 0.001 |
| Systolic BP, mmHg                             | 169.8 ± 24.6   | 186.1 ± 19.8| < 0.001 |
| Diastolic BP, mmHg                            | 88.3 ± 9.9     | 80.1 ± 10.7 | < 0.001 |
| RPP, mmHg.bpm                                 | 23052 ± 4889   | 30713 ± 4800| < 0.001 |
| Oxygen pulse, mL/beat                         | 13.5 ± 2.9     | 15.4 ± 3.8  | 0.008   |
| VE/VCO$_2$ slope                              | 31.8 ± 5.2     | 28.6 ± 4.4  | 0.004   |
| OUES                                          | 1963 ± 449.7   | 2555 ± 552  | < 0.001 |
| CP, mmHg.ml.kg$^{-1}$min$^{-1}$                | 3902 ± 1016    | 6099 ± 1403 | < 0.001 |
| VP, mmHg                                      | 5.5 ± 1.2      | 6.6 ± 1.3   | < 0.001 |
| Symptoms of dyspnea (0–10)                    | 6.0 [4 - 8]    | 4.5 [2 - 5] | 0.008   |
| Leg fatigue (0–10)                            | 7.0 [4 - 9]    | 4.5 [2 - 8] | < 0.001 |
| Angina, n (%)                                 | 1 (2)          | 0           | 0.230   |
| ST segment depression < 2 mm, n (%)           | 0              | 0           | -       |
| ST segment depression ≥ 2 mm, n (%)           | 0              | 0           | -       |
| **Aerobic functional classification, n (%)**   |                |             |         |
| Very weak                                     | 6 (14)         | 1 (2)       | 0.052   |
| Weak                                          | 22 (53)        | 3 (7)       | < 0.001 |
| Regular                                       | 14 (33)        | 24 (53)     | 0.083   |
| Good                                          | 0              | 15 (33)     | < 0.001 |
| Excellent                                     | 0              | 2 (5)       | 0.494   |

Data are presented as mean ± SD, median [minimum - maximum] or absolute values (%). CPX: cardiopulmonary exercise testing; AHA: American Heart Association; CAD-G: coronary artery disease group; CG: control group; n: number of subjects; HR: heart rate; BP: blood pressure; VO$_2$: oxygen uptake; RER: respiratory exchange ratio; % of predicted maximum HR: % of 220 minus age; Delta of HR peak HR minus HR at rest; RPP: rate-pressure product; VE/VCO$_2$ slope: linear relation between minute ventilation, and carbon dioxide production; OUES: linear relationship between oxygen uptake and minute ventilation; CP: circulatory power; VP: ventilatory power. Unpaired Student’s t-test and Fisher’s exact test.

Influenced peak VO$_2$ and peak systolic BP (as indicated by stepwise regression analysis), but did not influence CP and VP. Furthermore, the group influenced peak VO$_2$, the VE/VCO$_2$ slope, CP, and VP, while the number of vessels with stenosis after treatment influenced the VP. Thus, we believe that the lower values of CP and VP observed during CPX in CAD-G are related to standard medications, level of aerobic capacity and characteristics of CAD and that the reduction of VP in this population may also be related to number of vessels with stenosis after treatment.

One way to quantify exercise performance is by measuring peak VO$_2$. In the present study the lower values of this variable observed in CAD-G reinforce the role of CAD in a worse CPX response$^{10}$, which was also directly related to the ventilatory inefficiency observed in this group (higher VE/VCO$_2$ slope and lower OUES). High values of the VE/VCO$_2$ slope are often related to a worsening pulmonary hemodynamic profile and increased chemoreceptor and ergoreceptor activation, as well as decreased autonomic modulation and cardiovascular function$^7$. Lower OUES
values indicate that the extraction and utilization of oxygen is impaired because this variable is strongly correlated to VO$_2$. Furthermore, we observed in the present study that RPP and oxygen pulse were lower in CAD-G at peak CPX. RPP has been used as a relevant parameter in evaluating ventricular function, and high values at peak exercise are most likely related to good ventricular function and no ischemia. In addition, the oxygen pulse indicates the amount of oxygen consumed per heart beat, which reflects the efficiency of the cardiovascular system and may provide prognostic information in patients with CAD.

Another interesting and novel finding of this study was that subjects with a lower peak VO$_2$ presented with lower indices CP and VP that correlated with the aerobic functional classification according to AHA guidelines. A recent prospective study that evaluated the associations between exercise test parameters and all-cause mortality in patients without previous cardiovascular disease showed that poor exercise tolerance (determined by the observed duration of exercise in relation to the predicted duration) is associated with greater mortality risk. In our cross-sectional comparative study we observed that CP and VP positively correlated (strong and moderate correlation, respectively) with aerobic functional classification evaluated by peak VO$_2$.

Cohen-Solal et al. (2002) longitudinally evaluated (mean follow-up 25 ± 10 months) 175 heart failure patients who were subjected to an incremental CPX. Their study showed that CP was predictive of prognosis and that the combination of VO$_2$ and systolic BP (through the CP index) strengthens the prognostic value of CPX, particularly in subjects with low peak VO$_2$ and peak BP. Similar to the previous report, Forman et al. (2012) evaluated the prognostic use of VP in a longitudinal study (mean follow-up 4 years) with 875 heart failure patients submitted to CPX. The authors showed that VP was independently predictive of cardiac events compared with standard CPX indices (i.e., peak VO$_2$ and the VE/VCO$_2$ slope); furthermore, in a multivariate analysis, combined CP and VP provided even better prognostic discrimination. Although traditional variables obtained by CPX, such as VO$_2$, systolic BP, and the VE/VCO$_2$ slope, reflect the aerobic capacity, hemodynamic control and carbon dioxide production efficiency, respectively, CP and VP are indices that combine these variables. VP, as an index that combines systemic hemodynamics with carbon dioxide production efficiency during exercise, and CP as an index that combines central and peripheral components of cardiac stroke work, appear to both portend important information regarding disease severity and prognosis.

Recently, Borghi-Silva et al (2014) assessed the relationship between VP and key measures obtained using Doppler echocardiography in patients with heart failure and reduced ejection fraction; their results showed that lower values of VP translate into a very unfavorable phenotype characterized by a lower peak VO$_2$ and cardiac output response. The current study is a cross-sectional analysis with the goal of characterizing these indices in a CAD cohort under current standard pharmacologic regimens, angioplasty, or surgical management without heart failure. Our findings demonstrate that CP and VP are abnormal in CAD patients compared with healthy controls, and are related not only to standard medication but also to the level of aerobic capacity and characteristics of CAD; moreover, VP is related to the number of vessels with stenosis after treatment. Future work is needed to determine the prognostic utility of CP and VP in patients with CAD and establish whether both indices perform similarly to what has been found in patients with heart failure.

**Study limitations**

This investigation is characterized by an initial exploration of CP and VP indices in males with CAD; however, it has some limitations. First, although the literature...
indicates that CP and VP appear to be important prognostic markers in patients with heart failure, the cross-sectional nature and relatively small sample size of the current study did not allow us to expand upon prognostic utility. Therefore, additional prospective evaluations in this population are needed to determine the usefulness of these indices as prognostic markers. In relation to cardiac function, the CAD group was characterized only by left ventricular ejection fraction because 50% of patients were evaluated by ventriculography and 50% by echocardiogram. Women were not included in this study because the selected age could include both women with regular menstrual cycle (with and without use of contraceptives) and women in the postmenopausal stage (with and without use of hormone replacement therapy) and these differences could influence our results. Although the pharmacologic management of systemic arterial hypertension by angiotensin converting enzyme inhibitors, diuretics, and particularly beta-blockers may have influenced the behavior of CP and VP (as well as of other indices obtained from CPX), medication cessation is not possible because it is mandatory therapy for some patients. Future studies including a control group of systemic
arterial hypertension patients without CAD (with similar pharmacologic management to our study) could eliminate the possible influence of medications on studied variables.

Conclusions
The CP and VP indices were lower in men with CAD, without heart failure, and under current standard pharmacologic regimens, angioplasty, or surgical management than healthy controls, demonstrating a poorer cardiopulmonary function in this population. Our results suggest that both CP and VP may hold value as screening tools in assessing the functional significance of disease, exercise tolerance, and may consequently assist in the prescription of physical training in this population when used individually or complementarily to other indices currently attained by CPX. In fact, a multivariate approach including indices related to both central and peripheral function would likely provide a more comprehensive evaluation of exertional physiology. Future investigations are needed to evaluate if lower CP and VP values are due only to the CAD or to the use of standard pharmacologic regimens, as well as to verify the prognostic value of these indices in this patient population.

Acknowledgments
The authors would like to thank the patients for their effort and enthusiastic cooperation throughout the study and the physicians Sérgio Luiz Berti and João Orávio de Freitas Jr. for support with the hemodynamic section patients.

References
1. American Thoracic Society; American College of Chest Physicians. ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2003;167(2):211-77.

2. Sun XG, Hansen EJ, Garatachea N, Storer TW, Wasserman K. Ventilatory efficiency during exercise in healthy subjects. Am J Respir Crit Care Med. 2002;166(11):1443-8.

3. Baba R, Nagashima M, Masahiko N, Nagano Y, Yokota M, Tsuchi N, et al. Oxygen uptake efficiency slope: a new index of cardiopulmonary functional reserve derived from the relation between oxygen uptake and minute ventilation during incremental exercise. J Am Coll Cardiol. 1996;28(6):1567-72.

4. Baba R, Kubo N, Morotome Y, Iwagaki S. Reproducibility of the oxygen uptake efficiency slope in normal healthy subjects. J Sports Med Phys Fitness. 1999;39(3):202-6.

5. Arena R, Humphrey R, Peberdy MA. Prognostic ability of VE/VCO2 slope. J Card Fail. 2007;13(6):462-9.

6. Van Laethem C, Bartunek J, Goethals M, Nellens P, Andries E, Vanderheyden M. Oxygen uptake efficiency slope, a new index of cardiorespiratory functional reserve during exercise. J Am Coll Cardiol. 2005;45(1):175-80.

7. Arena R, Myers J, Hsu L, Peberdy MA, Pinkstaff S, Bensimhon D, et al. The minute ventilation/carbon dioxide production slope is prognostically superior to the oxygen uptake efficiency slope. J Card Fail. 2007;13(6):462-9.

8. Arena R, Myers J, Guazzi M. The clinical and research applications of aerobic capacity and ventilatory efficiency in heart failure: an evidence-based review. Heart Fail Rev. 2008;13(2):245-69.

9. Tsu Mugawa H, Kamachi H, Kurahashi M, Ohsima S, Taniguchi K. Prognostic impact of ventilatory efficiency in heart disease patients with preserved exercise tolerance. Circ J. 2006;70(10):1332-6.

10. Van de Veire NR, Van Laethem C, Philippé J, De Winter O, De Backer G, Vanderheyden M, et al. VE/VCO2 slope and oxygen uptake efficiency slope in patients with coronary artery disease and intermediate peak VO2. Eur J Cardiovasc Prev Rehabil. 2006;13(6):916-23.

11. Baba R, Tsuyuki K, Yano H, Ninomiya K, Ebine K. Robustness of the oxygen uptake efficiency slope to exercise intensity in patients with coronary artery disease. Nagoya J Med Sci. 2010;72(1-2):83-9.

12. Cohen-Solal A, Tabet JY, Logeart D, Bourgoin P, Vanderheyden M, Dahan M. A noninvasively determined surrogate of cardiac power (‘circulatory power’) at peak exercise is a powerful prognostic factor in chronic heart failure. Eur Heart J. 2002;23(10):806-14.

13. Giardini A, Specchia S, Bertone E, Sangiorgi D, Gargiulo G, et al. Strong and independent prognostic value of peak circulatory power in adults with congenital heart disease. Am Heart J. 2007;154(3):441-7.

14. Jaussaud J, Blanc P, Derval N, Bordachar P, Courregelongue E, Neves LMT. Ventilatory response and peak circulatory power: new functional markers of response after cardiac resynchronization therapy. Arch Cardiovasc Dis. 2010;103(3):184-91.

Author contributions
Conception and design of the research: Castello-Simões V, Catai AM. Acquisition of data: Castello-Simões V, Minatel V, Karsten M, Simões RP, Perseguini NM, Milan JC, Neves LMT. Analysis and interpretation of the data: Castello-Simões V, Minatel V, Karsten M, Simões RP, Perseguini NM, Milan JC, Arena R, Neves LMT, Catai AM. Statistical analysis: Castello-Simões V, Minatel V, Karsten M, Simões RP, Neves LMT, Borghi-Silva A. Obtaining financing: Castello-Simões V, Karsten M, Perseguini NM, Catai AM. Writing of the manuscript: Castello-Simões V, Karsten M, Simões RP, Catai AM. Critical revision of the manuscript for intellectual content: Castello-Simões V, Simões RP, Arena R, Borghi-Silva A, Catai AM.

Potential Conflict of Interest
No potential conflict of interest relevant to this article was reported.

Sources of Funding
This study was funded by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP), São Paulo/SP/Brasil (processos: 2010/52070-4); Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Brasília/DF/Brasil; Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Brasília/DF/Brasil (processo: 483945/2007-2).

Study Association
This article is part of the thesis of Doctoral submitted by Viviane Castello Simões, from Universidade Federal de São Carlos.
27. Vanhecke TE, Franklin BA, Miller WM, de Jong AT, Coleman CJ, McCullough PA. Cardiorespiratory fitness and sedentary lifestyle in the morbidly obese. Clin Cardiol. 2009; 32(3):121-4.

28. Castello-Simões V, Polaquini Simões R, Beltrame T, Basili D, Catali AM, Arena R, et al. Effects of aerobic exercise training on variability and heart rate kinetic during submaximal exercise after gastric bypass surgery—a randomized controlled trial. Disabil Rehabil. 2013; 35(4):334-42.

29. Tabet JY, Meurin P, Ben Driss AB, Thabut G, Weber H, Renaud N, et al. Determination of exercise training heart rate in patients on B-blockers after myocardial infarction. Eur J Cardiovasc Prev Rehabil. 2006;13(4):538-43.

30. Gallauria F, Galizia G, Lucci R, D’Agostino M, Vetelli A, Maresca L, et al. Favourable effects of exercise-based Cardiac Rehabilitation after acute myocardial infarction on left atrial remodeling. Int J Cardiol. 2010;136(3):300-6.

31. Fallahi B, Reiki D, Akbarpour S, Gholamrezaeehadvard A, Fard-Esfahani A, Akhazari F, et al. Withholding or continuing beta-blocker treatment before dipyridamole myocardial perfusion imaging for the diagnosis of coronary artery disease? A randomized clinical trial. Danu. 2013; 211(1):8.

32. Goblet FL, Nordstron LA, Nelson RR, Jorgensen CR, Wang Y. The rate-pressure product as an index of myocardial oxygen consumption during exercise in patients with angina pectoris. Circulation. 1978;57(3):549-56.

33. Fornitano LD, Godoy MF. Increased rate-pressure product as predictor for the absence of significant obstructive coronary artery disease in patients with positive exercise test. Arq Bras Cardiol. 2006;86(2):136-44.

34. Patterson RP, Remole WD. The response of the oxygen pulse during a stress test in patients with coronary artery disease. Cardiology. 1981;67(1):52-62.

35. Laukkaren JA, Karl S, Salonen JT, Lakk TA, Rautarama R. Peak oxygen pulse during exercise as a predictor for coronary heart disease and all cause death. Heart. 2006;92(9):1219-24.

36. Dhole BA, Lahr BD, Allison TG, Kopecky SL. Cardiopulmonary fitness and heart rate recovery as predictors of mortality in a referral population. J Am Heart Assoc. 2014;3(2):e000559.

37. Borghi-Silva A, Labate V, Arena R, Bandera F, Generati G, Pellegrino M, et al. Exercise ventilatory power in heart failure patients: functional phenotypes definition by combining cardiopulmonary exercise testing with stress echocardiography. Int J Cardiol. 2014;176(3):1348-9.

38. Neves VF, Silva de Sá MF, Gallo L Jr, Catali AM, Martins LE, Crescêncio JC, et al. Autonomic modulation of heart rate of young and postmenopausal women undergoing estrogen therapy. Braz J Med Biol Res. 2007;40(4):491-9.

39. Peresegini NM, de Medeiros Takahashi AC, Milan JC, dos Santos PR, Neves VF, et al. Effect of hormone replacement therapy on cardiac autonomic modulation. Clin Aut Res. 2014;24(2):63-70.